HOOKIPA Announces Promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer
March 22, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 22, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on March 24, 2022
March 17, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA to present new preclinical, translational, and clinical biomarker data at AACR further supporting the potential of arenaviral platform in oncology
March 08, 2022 16:51 ET
|
HOOKIPA Pharma Inc.
Four poster presentations expand evidence on potent T cell responses, ability to break tolerance and potential combination use beyond PD-1 inhibitorsPreclinical data suggest synergy of arenaviral...
HOOKIPA Pharma Announces Pricing of $75.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
March 02, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 02, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces Proposed Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
March 01, 2022 16:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, March 01, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (Nasdaq: HOOK), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA and Gilead Amend Collaboration and License Agreement to Develop Immunotherapies Against HIV
February 15, 2022 16:06 ET
|
HOOKIPA Pharma Inc.
HOOKIPA to develop arenaviral-based therapeutic for HIV through Phase 1b clinical trial completion; Gilead has exclusive rights for further program development thereafterFinancial terms include $15...
HOOKIPA to Present at the SVB Leerink Global Healthcare Conference
February 09, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Feb. 09, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
January 18, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...
HOOKIPA Pharma to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma to Participate in the JMP Securities Hematology and Oncology Summit
December 03, 2021 07:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Dec. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...